**参考文献**

[1] Li, S. & Mason, C. E. Te pivotal regulatory landscape of RNA modifcations. *Annu. Rev. Genomics Hum. Genet.* 15, 127–150 (2014)

[2] Desrosiers, R., Friderici, K. & Rottman, F. Identifcation of methylated nucleosides in messenger RNA from Novikof hepatoma cells. *Proc. Natl Acad. Sci. USA* 71, 3971–3975 (1974).

[3] Bokar, J. A., Shambaugh, M. E., Polayes, D., Matera, A. G. & Rottman, F. M. Purifcation and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N6 -adenosine)-methyltransferase. *RNA* 3, 1233–1247 (1997).

[4] Meyer, K. D. et al. Comprehensive analysis of mRNA methylation reveals enrichment in 3′ UTRs and near stop codons. *Cell* 149, 1635–1646 (2012).

[5] Śledź, P. & Jinek, M. Structural insights into the molecular mechanism of the m6 A writer complex. *Elife* 5, e18434 (2016).

[6] Wang, P., Doxtader, K. A. & Nam, Y. Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases. *Mol. Cell* 63, 306–317 (2016).

[7] Wang, X. et al. Structural basis of N6 -adenosine methylation by the METTL3–METTL14 complex. *Nature* 534, 575–578 (2016); erratum 542, 260 (2017).

[8] Liu, J. et al. A METTL3–METTL14 complex mediates mammalian nuclear RNA N6 -adenosine methylation. *Nat. Chem. Biol.* 10, 93–95 (2014).

[9] Yue, Y. et al. VIRMA mediates preferential m6 A mRNA methylation in 3′UTR and near stop codon and associates with alternative polyadenylation. *Cell Discov.* 4, 10 (2018).

[10] Liu, N. et al. Probing N6 -methyladenosine RNA modifcation status at single nucleotide resolution in mRNA and long noncoding RNA. *RNA* 19, 1848–1856 (2013).

[11] Darnell, R. B., Ke, S. & Darnell, J. E. Jr. Pre-mRNA processing includes N6 methylation of adenosine residues that are retained in mRNA exons and the fallacy of “RNA epigenetics”. *RNA* 24, 262–267 (2018).

[12] Li, F., Zhao, D., Wu, J. & Shi, Y. Structure of the YTH domain of human YTHDF2 in complex with an m6 A mononucleotide reveals an aromatic cage for m6 A recognition. *Cell Res*. 24, 1490–1492 (2014).

[13] Zhu, T. et al. Crystal structure of the YTH domain of YTHDF2 reveals mechanism for recognition of N6 -methyladenosine. *Cell Res*. 24, 1493–1496 (2014).

[14] Xu, C. et al. Structural basis for the discriminative recognition of N6 -methyladenosine RNA by the human YT521-B homology domain family of proteins. *J. Biol. Chem*. 290, 24902–24913 (2015).

[15] Xu, C. et al. Structural basis for selective binding of m6 A RNA by the YTHDC1 YTH domain. *Nat. Chem. Biol.* 10, 927–929 (2014).

[16] Wang, X. et al. N6 -methyladenosine-dependent regulation of messenger RNA stability. *Nature* 505, 117–120 (2014).

[17] Ries, R. J. et al. m6 A enhances the phase separation potential of mRNA. *Nature* 571, 424–428 (2019).

[18] Jia, G. et al. N6 -methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. *Nat. Chem. Biol.* 7, 885–887 (2011).

[19] Sommer, S., Lavi, U. & Darnell, J. E. Jr. Te absolute frequency of labeled N-6-methyladenosine in HeLa cell messenger RNA decreases with label time. *J. Mol. Biol.* 124, 487–499 (1978).

[20] Zhou, J. et al. N6 -methyladenosine guides mRNA alternative translation during integrated stress response. *Mol. Cell* 69, 636–647.e7 (2018).

[21] Lesbirel, S. et al. Te m6 A-methylase complex recruits TREX and regulates mRNA export. *Sci. Rep.* 8, 13827 (2018).

[22] Grozhik, A. V., Linder, B., Olarerin-George, A. O. & Jafrey, S. R. Mapping m6 A at individual-nucleotide resolution using crosslinking and immunoprecipitation (miCLIP). *Methods Mol. Biol*. 1562, 55–78 (2017).

[23] Liu, H. et al. Accurate detection of m6 A RNA modifcations in native RNA sequences. *Nat. Commun.* 10, 4079 (2019).

[24] Li Z, Weng H, Su R, Weng X, Zuo Z, Li C, Huang H, Nachtergaele S, Dong L, Hu C, et al. FTO plays an oncogenic role in acute myeloid leukemia as a N(6)-methyladenosine RNA demethylase. *Cancer cell*. 2017;31:127–41.

[25] Kwok CT, Marshall AD, Rasko JE, Wong JJ. Genetic alterations of m(6)A regulators predict poorer survival in acute myeloid leukemia. *J Hematol Oncol.* 2017;10:39.

[26] Wang Q, Chen C, Ding Q, Zhao Y, Wang Z, Chen J, Jiang Z, Zhang Y, Xu G, Zhang J, et al. METTL3-mediated m(6)A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance. *Gut*. 2019.

[27] Chen J, Sun Y, Xu X, Wang D, He J, Zhou H, Lu Y, Zeng J, Du F, Gong A, Xu M. YTH domain family 2 orchestrates epithelial-mesenchymal transition/ proliferation dichotomy in pancreatic cancer cells. *Cell Cycle*. 2017;16:2259–71.

[28] Lin S, Choe J, Du P, Triboulet R, Gregory RI. The m(6)A methyltransferase METTL3 promotes translation in human cancer cells. *Mol Cell.* 2016;62:335– 45.

[29] Sheng H, Li Z, Su S, Sun W, Zhang X, Li L, Li J, Liu S, Lu B, Zhang S, Shan C. YTH domain family 2 promotes lung cancer cell growth by facilitating 6- phosphogluconate dehydrogenase mRNA translation. *Carcinogenesis*. 2019.

[30] Cui Q, Shi H, Ye P, Li L, Qu Q, Sun G, Sun G, Lu Z, Huang Y, Yang CG, et al. m(6)A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells. *Cell Rep.* 2017;18:2622–34.

[31] Visvanathan A, Patil V, Arora A, Hegde AS, Arivazhagan A, Santosh V, Somasundaram K. Essential role of METTL3-mediated m(6)A modification in glioma stem-like cells maintenance and radioresistance. *Oncogene.* 2018;37: 522–33.

[32] Li J, Meng S, Xu M, Wang S, He L, Xu X, Wang X, Xie L. Downregulation of N(6)-methyladenosine binding YTHDF2 protein mediated by miR-493-3p suppresses prostate cancer by elevating N(6)-methyladenosine levels. *Oncotarget.* 2018;9:3752–64.

[33] Zhang C, Zhi WI, Lu H, Samanta D, Chen I, Gabrielson E, Semenza GL. Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells. *Oncotarget*. 2016;7:64527–42.

[34] Liu J, Eckert MA, Harada BT, Liu SM, Lu Z, Yu K, Tienda SM, Chryplewicz A, Zhu AC, Yang Y, et al. m(6)A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. *Nat Cell Biol.* 2018;20:1074–83.

[35] Jia R, Chai P, Wang S, Sun B, Xu Y, Yang Y, Ge S, Jia R, Yang YG, Fan X. m(6)A modification suppresses ocular melanoma through modulating HINT2 mRNA translation. *Mol Cancer*. 2019;18:161.